IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors

In conclusion, IGH/MYC–positive Burkitt lymphoma/leukemia cells have decreased BRCA2 and are sensitive to PARP1 inhibition alone or in combination with other chemotherapies. Implications: This study postulates that IGH/MYC–induced BRCA2 deficiency may predispose Burkitt lymphoma cells to synthetic lethality triggered by PARP1 inhibitors. Visual Overview: http://mcr.aacrjournals.org/content/molcanres/15/8/967/F1.large.jpg. Mol Cancer Res; 15(8); 967–72. ©2017 AACR.

http://mcr.aacrjournals.org/cgi/content/short/15/8/967?rss=1

Source: Molecular Cancer Research - August 1, 2017 Category: Cancer & Oncology Authors: Maifrede, S., Martin, K., Podszywalow-Bartnicka, P., Sullivan-Reed, K., Langer, S. K., Nejati, R., Dasgupta, Y., Hulse, M., Gritsyuk, D., Nieborowska-Skorska, M., Lupey-Green, L. N., Zhao, H., Piwocka, K., Wasik, M. A., Tempera, I., Skorski, T. Tags: Rapid Impact Source Type: research